Navigation Links
Fibril Shape Is The Basis Of Prion Strains And Cross-species Prion Infection

New research on prions, the infectious proteins behind "mad cow" disease and Creutzfeld-Jakob disease in humans, suggests that the ability of prions in one species to infect other species depends on the shape of the toxic threadlike fibers produced by the prion. Two studies on the topic appear in the 8 April issue of the journal Cell.

Although research suggests that prions from one species rarely infect other species, some scientists believe the species barrier was breached when a new version of Creutzfeld-Jakob disease appeared in humans after several recent epidemics of bovine spongiform encephalopathy or "mad cow" disease. Since then, barriers to the transmission of prion diseases between species "have emerged as a major public health issue," according to Eric Jones and Witold Surewicz of Case Western Reserve University.

Prion diseases are caused by misfolded variants of the normal prion protein, which aggregate into fibrous tangles called amyloid fibrils and cause fatal wasting of brain tissue. The abnormally folded protein itself appears to act as an infectious agent, transmitting disease without a DNA or RNA genome such as in a virus. Although disease prions seem to infect normal prions by binding to them and forcing them to take on the abnormal configuration, researchers remain uncertain about the exact molecular details of infection.

Earlier studies identified many "strains" of disease prions across mammalian and yeast species. Researchers thought these strains could be defined by differences in the underlying amino acid sequences of the prions. Under this scenario, disease transmission would be more likely between species with similar prion amino acid sequences.

But a few mysteries stood in the way: Some individuals harbored several different prion strains that caused different disease outcomes, even though all the prions shared the same amino acid sequence. In some cases, a single amino acid change in one species could compl etely change its ability to infect a previously "off-limits" species, Surewicz and colleagues found.

In a study published last year in the journal Molecular Cell, Surewuicz and colleagues also demonstrated that a "preseeding" process between animals with different prion amino acid sequences could overcome species barriers. For instance, mouse prion fibrils normally infect humans but not hamsters. But when mouse prions were brought into contact with hamster prion amyloid fibrils, a new strain of mouse fibrils emerged with the ability to infect hamsters but not humans. The new mouse strain had the same amino acid sequence as the original mouse strain but completely different infectious capabilities.

With the help of atomic-level microscopic observation of prions in humans, mice, and hamsters, Jones and Surewicz discovered that it is the specific shape of the amyloid fibrils, and not the amino acid sequences, that may allow prions from one species to infect another.

In a second Cell study, Jonathan Weissman and colleagues at the University of California, San Francisco came to the same conclusion in their experiments with yeast. They too discovered that the particular shape of a prion amyloid fibril was the determining factor in whether one species of yeast could infect another yeast species.

Just as in the case with the preseeded mice fibrils, a particular fibril shape in Saccharomyces cerevisiae yeast allowed prion transmission to Candida albicans yeast. The transmission event led to a new strain of Candida prion fibrils that could in turn infect Saccharomyces.

Although fibril shape appears to be the deciding infective factor, amino acid sequence is still important because it defines a set of possible preferred fibril shapes that prions can adopt, Weissman says. Species with similar amino acids sequences share an overlapping set of shapes, which helps explain why species with shared sequences have the ability to infect each othe r.

Surewicz says the next step in their research will be to examine fibril shape differences at much higher resolution. Their experiments also used a shortened version of the mammalian prion protein, so they hope to test the fibril factor in a full-length protein soon.

Jones and Surewicz also note that the new findings offer "the unsettling possibility" that repeated cross-species transmission events might eventually create prion fibril strains that can bridge the infection gap between previously separate animals like humans and elk and deer, which suffer from a prion disease called chronic wasting disease.

Surewicz stresses, however, prion infection between species is still rare. "Fortunately, transmission by eating is very ineffective. There have been hundreds of thousands of bovine spongiform encephalopathy cases, for example, and lots of people exposed to tainted beef products, but very few cases of variant Creutzfeld-Jakob."

He says there "must be protective mechanisms working there, but we don't know what they are."

The other members of the Weissman research team include Motomasa Tanaka and Peter Chien. The Weissman study was supported by Howard Hughes Medical Institute, The David and Lucile Packard Foundation, and the National Institutes of Health. The Jones and Surewicz study was supported by the National Institutes of Health.

Eric M. Jones and Witold K. Surewicz: "Fibril Conformation as the Basis of Species-and Strain-Dependent Seeding Specificity of Mammalian Prion Amyloids"

Motomasa Tanaka, Peter Chien, Koji Yonekura, and Jonathan S. Weissman: "Mechanism of Crossspecies Prion Transmission: An Infectious Conformation Compatible with Two Highly Divergent Yeast Prion Proteins"

Publishing in Cell, Volume 121, Number 1, April 8, 2005. http:/?​www.cell.com


'"/>

Source:Cell Press


Related biology news :

1. The Shapes Of Life: NIGMS Project Yields More Than 1,000 Protein Structures
2. Basis for DNA ejection from single phage particles
3. Active Vaccine Prevents Mice From Developing Prion Disease
4. Prions rapidly remodel good protein into bad, Brown study shows
5. Prion find points way to test for human mad cow disease
6. Prion disease treatable if caught early
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... MedNet Solutions , an innovative ... spectrum of clinical research, is proud to announce ... the organization in terms of corporate growth, outside ... and services. The company,s exceptional achievements can be ... iMedNet ™ – MedNet,s ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... spanning the full spectrum of drug and device development, and Prism Clinical ... companies and clinicians, today announced Verified Clinical Trials (VCT) has been ...
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
Breaking Biology Technology: